Cowen Trims TransMedics Group (NASDAQ:TMDX) Target Price to $28.00

Share on StockTwits

TransMedics Group (NASDAQ:TMDX) had its price target cut by Cowen from $40.00 to $28.00 in a research report sent to investors on Thursday, The Fly reports. They currently have an outperform rating on the stock.

Separately, Zacks Investment Research raised shares of TransMedics Group from a sell rating to a hold rating in a research note on Sunday, November 3rd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $33.00.

NASDAQ TMDX traded up $0.34 during trading hours on Thursday, hitting $16.95. 229,900 shares of the company’s stock traded hands, compared to its average volume of 146,987. The stock has a fifty day simple moving average of $19.50. The company has a current ratio of 7.55, a quick ratio of 6.82 and a debt-to-equity ratio of 0.48. TransMedics Group has a 52 week low of $15.74 and a 52 week high of $31.54.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $6.67 million. Sell-side analysts predict that TransMedics Group will post -2.25 EPS for the current year.

A number of hedge funds have recently bought and sold shares of TMDX. Roubaix Capital LLC bought a new position in TransMedics Group during the second quarter valued at $4,962,000. Janus Henderson Group PLC bought a new position in shares of TransMedics Group in the second quarter worth about $15,059,000. Emerald Advisers LLC bought a new position in shares of TransMedics Group in the second quarter worth about $6,132,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of TransMedics Group in the second quarter worth about $5,697,000. Finally, Lisanti Capital Growth LLC bought a new position in shares of TransMedics Group in the second quarter worth about $1,063,000. Institutional investors and hedge funds own 65.88% of the company’s stock.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Article: Marijuana Stocks

The Fly

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BMO Capital Markets Trims Grand Canyon Education  Target Price to $116.00
BMO Capital Markets Trims Grand Canyon Education Target Price to $116.00
Base Resources  Rating Reiterated by Berenberg Bank
Base Resources Rating Reiterated by Berenberg Bank
BioLife Solutions  Raised to “Strong-Buy” at BidaskClub
BioLife Solutions Raised to “Strong-Buy” at BidaskClub
Cowen Trims TransMedics Group  Target Price to $28.00
Cowen Trims TransMedics Group Target Price to $28.00
Zacks: OFS Credit Company Inc  Receives Average Recommendation of “Strong Buy” from Brokerages
Zacks: OFS Credit Company Inc Receives Average Recommendation of “Strong Buy” from Brokerages
Aerie Pharmaceuticals  Stock Rating Reaffirmed by Cowen
Aerie Pharmaceuticals Stock Rating Reaffirmed by Cowen


© 2006-2019 Ticker Report